Welcome to our dedicated page for Allogene Therapeutics SEC filings (Ticker: ALLO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Allogene Therapeutics SEC filings document the regulatory record of a clinical-stage biotechnology company developing allogeneic CAR T product candidates. The filings cover material-event reports, operating and financial updates, common stock registration and offering activity, and clinical disclosures involving programs such as cema-cel in large B-cell lymphoma and ALLO-329 in autoimmune disease.
Allogene's proxy materials describe annual meeting proposals, shareholder voting matters, board governance, executive compensation, and equity award disclosures. Other filings address Nasdaq-listed common stock, capital-structure changes, material agreements, and risk factors tied to research and development, clinical execution, regulatory matters, intellectual property, and licensed gene-editing technology used in its allogeneic CAR T programs.
Allogene Therapeutics insider Zachary Roberts has filed a Form 144 notice to sell 35,700 shares of common stock, with an aggregate market value of $63,353.22, through Morgan Stanley Smith Barney on NASDAQ around February 2, 2026.
The shares were acquired on January 31, 2026 via restricted stock vesting under a registered compensation plan, with 224,730,144 common shares outstanding. In the prior three months, Roberts sold 26,269 common shares for gross proceeds of $40,979.64. The filer represents they are not aware of undisclosed material adverse information about Allogene.
Allogene Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 4,167 shares of Allogene Therapeutics common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,177.66. The shares were acquired on January 31, 2026 through restricted stock vesting under a registered compensation plan.
The planned sale is expected to occur around February 2, 2026 on the NASDAQ exchange. As of the notice, 224,730,144 shares of Allogene common stock were outstanding, providing context for the relative size of this planned transaction.
A planned sale notice under Rule 144 covers 243,976 shares of Common Stock, to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ market. The shares have an aggregate market value of 438,522.46 and are part of a total of 224,730,144 shares outstanding.
The seller acquired these shares as restricted stock vesting under a registered plan from the issuer on 01/31/2026, treated as compensation. The approximate planned sale date is 02/02/2026, and the signer represents not knowing any undisclosed material adverse information about the issuer’s operations.
A holder of common stock has filed a Form 144 notice to potentially sell 16,823 shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an indicated aggregate market value of $29,051.64. The issuer reports 224,730,144 shares of common stock outstanding.
The shares to be sold were acquired as restricted stock vesting under a registered plan on January 31, 2026, treated as compensation from the issuer. The same individual previously sold 786 common shares on November 17, 2025, generating gross proceeds of $958.92.
Allogene Therapeutics, Inc. reported an insider transaction by EVP of R&D Zachary RobertsJanuary 21, 2026, Roberts sold 26,269 shares of Allogene common stock at $1.56 per share. According to the filing, these shares were sold solely to cover tax withholding obligations arising from the vesting of restricted stock units, under a mandated “sell to cover” election in the company’s equity incentive plan, and are not a discretionary trade by Roberts.
Following this transaction, Roberts beneficially owned 616,866 shares of Allogene common stock in direct ownership.
Allogene Therapeutics, Inc. has a planned sale of 26269 shares of common stock, as disclosed in a Form 144 notice. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 01/21/2026 and an aggregate market value of 40929.05.
The securities were acquired on 01/20/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan. Shares outstanding were 224730144 at the time of the notice; this is a baseline figure, not the amount being sold.
Allogene Therapeutics (ALLO) reported an insider transaction by its SVP and Chief Technical Officer on a Form 4. On 11/17/2025, the executive sold 786 shares of common stock at a weighted average price of $1.22 per share, with individual trade prices ranging from $1.22 to $1.23. The filing explains that these shares were sold solely to cover tax withholding obligations triggered by the vesting of restricted stock units under the company’s equity incentive plan, and that this was a mandated "sell to cover" transaction rather than a discretionary sale. Following this small sale, the reporting person beneficially owns 217,721 shares of Allogene common stock.
Allogene Therapeutics (ALLO) reported Q3 2025 results showing a narrower net loss of $41.4 million versus $66.3 million a year ago as operating expenses fell to $44.9 million from $71.8 million. Interest and other income contributed $3.5 million in the quarter.
Liquidity and runway: Cash, cash equivalents and investments were $277.1 million as of September 30, 2025, and management stated these resources are expected to fund operations for at least 12 months from the filing date. Net cash used in operating activities was $121.6 million for the nine months ended September 30, 2025.
Capital actions and structure: The company sold 7,477,047 shares via its ATM in the nine months ended September 30, 2025, generating $14.5 million in net proceeds. Shares issued and outstanding were 223,163,672 as of September 30, 2025; 224,730,144 were outstanding as of November 4, 2025.
Operations and costs: R&D expense was $31.2 million in Q3 (down from $44.7 million), and G&A was $13.7 million (down from $16.3 million). Year-to-date impairment of long-lived assets was $2.4 million, including effects related to subleased facilities. A workforce reduction approved in May 2025 (approximately 28%) resulted in $4.7 million of charges year-to-date.
Programs and funding: The company received $9.2 million to date under the CIRM award tied to ALLO‑316, recorded as a liability; related interest expense was $0.8 million year-to-date.
Allogene Therapeutics (ALLO) furnished an 8‑K stating it provided a corporate update and announced financial results for the quarter ended September 30, 2025. The details are contained in a press release attached as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act, nor incorporated by reference unless specifically stated. Common stock trades on Nasdaq under ALLO.
Allogene Therapeutics (ALLO) reported an insider transaction by its Chief Financial Officer. On 10/21/2025, the CFO sold 36,744 shares of common stock at $1.2565 per share. The filing states this was a mandated sell-to-cover to satisfy tax withholding from restricted stock unit vesting and not a discretionary trade.
Following the transaction, the CFO beneficially owned 1,276,796 shares directly. The holdings include shares acquired via the employee stock purchase program: 6,000 shares on March 14, 2025 and 6,000 shares on September 15, 2025.